The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain
Open accessAbstract
Objective To compare the efficacy and safety of SC depot medroxyprogesterone acetate (DMPA-SC 104) with that of leuprolide acetate in treatment of endometriosis.Design Phase 3, multicenter, randomized, evaluator-blinded, comparator-controlled trial.Setting Clinical trial sites in Canada and United States.Patient(s) Two hundred seventy-four women with surgically diagnosed endometriosis.Intervention(s) Intramuscular injections of DMPA-SC (104 mg) or leuprolide acetate (11.25 mg), given every 3 months for 6 months, with 12 months of posttreatment follow-up.Main outcome measure(s) Reduction in five endometriosis symptoms or signs (dysmenorrhea, dyspareunia, pelvic pain, pelvic tenderness, pelvic induration); change in bone mineral density (BMD), hypoestrogenic symptoms, bleeding, and weight.Result(s) The depot medroxyprogesterone acetate given SC was statistically equivalent to leuprolide in reducing four of five endometriosis symptoms or signs at the end of treatment (month 6) and in reducing all five symptoms after 12 months' follow-up (month 18). Patients in the DMPA-SC 104 group showed significantly less BMD loss than did leuprolide patients at month 6, with scores returning to baseline at 12 months' follow-up. No statistically significant differences in median weight changes were observed between groups. Compared with leuprolide, DMPA-SC 104 was associated with fewer hypoestrogenic symptoms but more irregular bleeding.Conclusion(s) Efficacy of DMPA-SC 104 was equivalent to that of leuprolide for reducing endometriosis-associated pain, with less impact on BMD and fewer hypoestrogenic side effects but more bleeding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depot medroxyprogesterone acetate (MPA; 104 mg, subcutaneous injection, every 3 months) has demonstrated an efficacy equivalent to LA, but long-term use of depot MPA preparations is shown to impact adversely on bone mineral density (BMD), while the delay in resumption of ovulation that may follow discontinuation of this therapy is a contraindication to use in women wishing to conceive in the near”
From Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial (2010) · cites this paper as Schlaff et al., 2006
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MPA appeared to be more effective than placebo [214] and as effective as danazol [215] and GnRH-agonists [216, 217] in reducing endometriosis-related pain.”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [217]
The cited source says what the claim attributes to it.
In the citing paper
“Irregular uterine bleeding is a known adverse effect of treatment with progestins, including depot preparations of MPA, which have been compared in trials against LA (Vercellini et al., 2003;Crosignani et al., 2006;Schlaff et al., 2006).”
From Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial (2010) · cites this paper as Schlaff et al., 2006
In the citing paper
“In both studies DMPA-SC was statistically equivalent to GnRHa in reducing pain symptoms after 12 months' follow-up.”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [51]
In the citing paper
“Patients in the DMPA-SC group showed significantly less BMD loss than did leuprolide patients at month 6.”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [51]
In the citing paper
“Progestins were positively associated with HRQoL in women with endometriosis [20,21,23-25,27,29,30].”
From Health-related quality of life in women with endometriosis: a systematic review (2012) · cites this paper as [25]
In the citing paper
“Six months of GnRHa treatment improved women’s HRQoL even at one year after treatment, according to the SF-36 questionnaire [24-27,29], as well as work-related indexes [18,20].”
From Health-related quality of life in women with endometriosis: a systematic review (2012) · cites this paper as [25]
In the citing paper
“Moreover, six months of therapy with progestins seemed equivalent to that of GnRHa in improving HRQoL and reducing pain, according to six RCTs [20,23-25,27,29].”
From Health-related quality of life in women with endometriosis: a systematic review (2012) · cites this paper as [25]
In the citing paper
“Subcutaneous injections of depomedroxyprogesterone acetate (104 mg/0.65 mL) improved all pre-specified scales of the EHP-30 and SF-36 from baseline to the end of the 6-month treatment and even at the 18-month follow-up [24,25].”
From Health-related quality of life in women with endometriosis: a systematic review (2012) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Friedman, A. J., & Hornstein, M. D. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56090-7 · Cited by 47
RetractedDlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279
Leuprolide Acetate Depot and Hormonal Add-Back in Endometriosis: A 12-Month Study
Hornstein, M. D. (1998) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(97)00620-0 · Cited by 244
Progestins for symptomatic endometriosis: a critical analysis of the evidence
Vercellini, P., Cortesi, I., & Crosignani, P. G. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00193-3 · Cited by 229
Contraceptive efficacy and safety of DMPA-SC
Jain, J. K., Jakimiuk, A. J., Bode, F. R., Ross, D., & Kaunitz, A. M. (2004) · Contraception · doi:10.1016/j.contraception.2004.06.011 · Cited by 178
Self-citationSchwallie, P. C., & Assenzo, J. R. (1973) · Fertility and Sterility · doi:10.1016/s0015-0282(16)39669-8 · Cited by 167
Cosson, M., Querleu, D., Donnez, J., Madelenat, P., Konincks, P., Audebert, A., & Manhes, H. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03270-8 · Cited by 153
Endometriosis: Treatment Strategies
VALLE, R. F., & Sciarra, J. J. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1290.026 · Cited by 151
Westhoff, C. L. (2003) · Contraception · doi:10.1016/s0010-7824(03)00136-7 · Cited by 146
Lockhat, F. B. (2004) · Human Reproduction · doi:10.1093/humrep/deh004 · Cited by 135
Conventional Medical Therapies for Endometriosis
Rice, V. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02795.x · Cited by 127
Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis.
Luciano, A. A., Turksoy, R. N., & Carleo, J. (1988) · PubMed · Cited by 122
Self-citationStatistical Considerations for Multiplicity in Confirmatory Protocols
Koch, G. G., & Gansky, S. A. (1996) · Drug Information Journal · doi:10.1177/009286159603000228 · Cited by 116
Depot-medroxyprogesterone acetate (dmpa) and risk of edometrial cancer
CONTRACEPTIVES, T. W. C. S. O. N. A. S., Cuevas, H. R., Salazar, S. B., Palet, A., Ontiveros, P., Silpisornkosol, S., Pardthaisong, T., Charoeniam, V., Theetranont, S., Boosiri, B., et al. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490208 · Cited by 111
Ovarian and endometrial function during hormonal contraception
The ESHRE Capri Workshop Group (2001) · Human Reproduction · doi:10.1093/humrep/16.7.1527 · Cited by 103
Changes in quality of life after hormonal treatment of endometriosis
Bergqvist, A., & Theorell, T. (2001) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1034/j.1600-0412.2001.800708.x · Cited by 98
Self-citationOverton, C. E., Lindsay, P., Johal, B., Collins, S. A., Siddle, N., Shaw, R. W., & Barlow, D. H. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56991-x · Cited by 97
Breast cancer and depot-medroxyprogesterone acetate: a multinational study
(1991) · The Lancet · doi:10.1016/0140-6736(91)91498-j · Cited by 86
Ka, R., & Db, T. (1991) · PubMed · Cited by 84
Ovarian and endometrial function during hormonal contraception
Baird, D. T., Collins, J. A., Cooke, I. D., Glasier, A. F., Jacobs, H. S., Vecchia, C. L., Stock, G. J., Vercellini, P., Cohen, J., Crosignani, P. G., et al. (2001) · Human Reproduction · Cited by 61
Current place of progestins in the treatment of endometriosis-related complaints
Schweppe, K.-W. (2001) · Gynecological Endocrinology · doi:10.1080/gye.15.s6.22.28 · Cited by 54
Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer
Neop, T. W. C. S. O. (1992) · Contraception · doi:10.1016/0010-7824(92)90052-u · Cited by 46
Rotondi, M., Labriola, D., Rotondi, M., Ammaturo, F. P., Amato, G., Carella, C., Izzo, A., & Panariello, S. (2002) · PubMed · Cited by 33
Db, T., & Rm, R. (1992) · Contraception · Cited by 30
Hormonal contraception without estrogens
The ESHRE Capri Workshop Group (2003) · Human Reproduction Update · doi:10.1093/humupd/dmb025 · Cited by 27
Evaluation of the Role of Laser Treatment for the Treatment of Pain in Endometriosis
Shaw, R. W. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1290.027 · Cited by 15
Flagged first, then by citations
1 of the 28 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381
Systematic review of endometriosis pain assessment: how to choose a scale?
Bourdel, N., Alves, J., Pickering, G. P., Ramilo, I. D. T. M., Roman, H., & Canis, M. J. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu046 · Cited by 378
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Reevaluating response and failure of medical treatment of endometriosis: a systematic review
Becker, C. M., Gattrell, W. T., Gude, K., & Singh, S. S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.05.004 · Cited by 302
Metadata
- Authors
- Schlaff, W. D., Carson, S. A., Luciano, A., Ross, D., & Bergqvist, A.
- Affiliations
- University of Colorado Health (US)
- Baylor College of Medicine (US)
- University of Connecticut (US)
- Pfizer (United States) (US)
- Karolinska Institutet (SE)
- Corresponding author
- Schlaff, William D.
- ORCID
- Luciano, Anthony
- Venue
- Fertility and Sterility
- Publisher
- Elsevier BV
- Published
- 2006-02
- Volume
- 85
- Issue
- 2
- Pages
- 314-325
- ISSN
- 0015-0282 (ISSN-L)
- OpenAlex
- W2017780870
- Semantic Scholar
- e24478c88204964afa49b33817b516679f38a0a8
- Cited by
- 168
- References
- 28
- Citations by year
- 2026: 8 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 1 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 11 · 2017: 8 · 2016: 4 · 2015: 14 · 2014: 7 · 2013: 13 · 2012: 11
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Fertility and Sterility (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- endometriosis, endometriosis-associated pain, depot medroxyprogesterone acetate, leuprolide, GnRH agonist, GnRH antagonist, subcutaneous injection, bone mineral density, dysmenorrhea, dyspareunia, pelvic pain, irregular bleeding, weight change
- MeSH terms
- Adult, Delayed-Action Preparations, Endometriosis, Estrogens, Female, Flushing, Humans, Injections, Subcutaneous, Pain, Palliative Care, Quality of Life, Uterine Hemorrhage, Bone Density, Single-Blind Method, Leuprolide, Treatment Outcome, Medroxyprogesterone Acetate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
